Press Release

View printer-friendly version << Back
Juniper Pharmaceuticals to Present at Rodman & Renshaw Global Investment Conference on September 12, 2016

BOSTON, Aug. 31, 2016 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), announced today that Alicia Secor, President and Chief Executive Officer, will present at the Rodman & Renshaw 18th Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC., as follows:


18th Annual Rodman & Renshaw Global Investment Conference


Monday, September 12, 2016


9:35 a.m. EDT  


Kennedy II (4th Floor), Lotte New York Palace Hotel, NYC


Juniper Pharmaceuticals, Inc. (PRNewsFoto/Juniper Pharmaceuticals, Inc.)

Juniper's presentation will be webcast live via under the 'Investors' tab, or click here.  The webcast will be archived for 90 days at the aforementioned URLs.

In addition to the live presentation, Ms. Secor and George O. Elston, Juniper's Chief Financial Officer, will be available for one-on-one meetings with investors who are registered to attend the conference.

Institutional investors wishing to attend Juniper's presentation may visit to register for the Rodman & Renshaw conference.  Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

About Juniper Pharmaceuticals
Juniper Pharmaceuticals, Inc. is focused on developing therapeutics to address unmet medical needs in women's health.  The Company is advancing a pipeline of proprietary product candidates that leverage its differentiated intravaginal ring technology and the 505(b)(2) regulatory pathway.  Juniper's core operating business includes the Crinone® (progesterone gel) franchise and Juniper Pharma Services, which provides high-end fee-for-service pharmaceutical development and clinical trials manufacturing to clients.  Please visit for more information.

Juniper Pharmaceuticals™ is a trademark of Juniper Pharmaceuticals, Inc., in the U.S. and EU.

Crinone® is a registered trademark of Merck KGaA, Darmstadt, Germany, outside the U.S. and of Allergan, Inc. in the U.S.

Amy Raskopf
Director, Corporate Communications, Juniper Pharmaceuticals, Inc.
(917) 673-5775 /

To receive Juniper's press releases, SEC filings or calendar alerts by email click here.
Follow us on LinkedIn

Logo -

To view the original version on PR Newswire, visit:

SOURCE Juniper Pharmaceuticals, Inc.